Tech Company Financing Transactions
Viamet Pharmaceuticals Funding Round
Viamet Pharmaceuticals closed a $7 million Series C funding round on 6/17/2013. Backers included private investors.
Transaction Overview
Company Name
Announced On
6/17/2013
Transaction Type
Venture Equity
Amount
$7,000,000
Round
Series C
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. SEC regulatory filing-amended.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
4505 Emperor Blvd. 300
Durham, NC 27703
USA
Durham, NC 27703
USA
Phone
Website
Email Address
Not Recorded
Overview
Viamet Pharmaceuticals discovers and develops best-in-class inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, our Metallophile Technology.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robert Schotzinger
Chief Medical Officer
Oren Cohen
VP - Product Management
Thorsten Degenhardt
Browse more venture capital transactions:
Prev: 6/17/2013: Silvergate Pharmaceuticals venture capital transaction
Next: 6/17/2013: Fullscreen venture capital transaction
Share this article
About Our VC Transactions Data
Our team works diligently to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs